Private Advisor Group LLC lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 43.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,221 shares of the medical research company’s stock after selling 6,352 shares during the quarter. Private Advisor Group LLC’s holdings in Thermo Fisher Scientific were worth $1,647,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in TMO. Amalgamated Bank raised its position in shares of Thermo Fisher Scientific by 57.0% in the second quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after purchasing an additional 16,308 shares during the period. Mutual of America Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 2.1% in the second quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after purchasing an additional 977 shares during the period. Americafirst Capital Management LLC bought a new position in shares of Thermo Fisher Scientific in the third quarter valued at about $876,000. Rockland Trust Co. raised its position in shares of Thermo Fisher Scientific by 7.3% in the fourth quarter. Rockland Trust Co. now owns 62,332 shares of the medical research company’s stock valued at $11,836,000 after purchasing an additional 4,221 shares during the period. Finally, San Francisco Sentry Investment Group CA bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at about $1,451,000. Hedge funds and other institutional investors own 86.11% of the company’s stock.
Thermo Fisher Scientific Inc. (NYSE:TMO) opened at $210.61 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $151.74 and a 1 year high of $226.44. The company has a market cap of $84,450.00, a PE ratio of 34.53, a P/E/G ratio of 1.53 and a beta of 1.11. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the firm earned $2.41 EPS. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. analysts anticipate that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be issued a $0.17 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a yield of 0.32%. The ex-dividend date of this dividend is Wednesday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.84%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the transaction, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at approximately $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Gregory J. Herrema sold 33,327 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the transaction, the senior vice president now directly owns 60,471 shares in the company, valued at $13,285,478.70. The disclosure for this sale can be found here. Over the last three months, insiders sold 94,327 shares of company stock worth $19,260,542. Insiders own 0.49% of the company’s stock.
TMO has been the topic of several research analyst reports. BTIG Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, January 5th. They issued a “buy” rating and a $230.00 price objective on the stock. Bank of America increased their price objective on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Leerink Swann reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Monday, October 30th. Deutsche Bank set a $226.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. Finally, Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a research report on Tuesday, October 31st. Two analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $220.50.
ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/17/thermo-fisher-scientific-inc-tmo-holdings-reduced-by-private-advisor-group-llc.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.